During the past decade, Vanderbilt University Medical Center, Dept. of Urologic Surgery conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" #1 sponsor was "CG Oncology, Inc." with 2 trials, followed by "Photocure" with 2 trials sponsored, "Cook MyoSite" with 1 trials sponsored, "Ferring Pharmaceuticals" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "FKD Therapies Oy" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Society of Urologic Oncology Clinical Trials Consortium" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" are "Bladder Cancer" (4 trials), "Cancer of the Prostate" (1 trials), "Carcinoma in Situ" (1 trials), "Carcinoma in Situ Concurrent With Papillary Tumors" (1 trials) and "Nonmetastatic Castration-Resistant Prostate Cancer" (1 trials). Many other conditions were trialed in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" in a lesser frequency.

Most popular intervention types in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" are "Biological" (4 trials), "Drug" (2 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ADSTILADRIN" (1 trials), "AMDC-USR (iltamiocel)" (1 trials), "CG0070" (1 trials) and "CG0070 Adenovirus Vector" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vanderbilt University Medical Center, Dept. of Urologic Surgery" are 5 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Vanderbilt University Medical Center, Dept. of Urologic Surgery". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Vanderbilt University Medical Center, Dept. of Urologic Surgery, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Vanderbilt University Medical Center, Dept. of Urologic Surgery, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".